EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    What Changes at Scale, and How Do You Know?

    A pharmaceutical process that performs reliably on a few grams of material can behave very differently at pilot or commercial scale The temperature setpoint that worked on the bench the mixing time that delivered a uniform blend the feed rate that kept a reaction on track none of these is guaranteed to mean the same thing in larger equipment When that difference goes...

KNOWLEDGE BANK

  • Articles

    Advertise Smarter with the 2025 Pharma Focus Europe Media Pack

    The internet has forever changed the healthcare industry and it is no longer whether to advertise but how to advertise better in the changing digital world Following the shift of pharma marketing to precision personalization and performance Pharma Focus Europe Media Pack is precisely your prescription to be the best in terms of competing in the European market

    Breaking Down Barriers: Advancements in Biodegradable Drug Delivery

    In todays world where sustainability is a top priority breaking down barriers to a greener future is crucial One area where advancements are being made is in the field of biodegradable drug delivery

    Rethinking Make-or-Buy: Strategic Manufacturing Decisions in Pharma

    Few strategic decisions in pharmaceutical operations carry as much longterm consequence as the choice of what to make and what to buy and few are revisited as rarely Network footprints agreed a decade ago partners selected during a capacity crunch technology transfers completed under launch pressure these choices harden into architecture They stop looking like decisions and start looking like the...

    The Rise of Continuous Clinical Trials: Redefining Drug Development

    The conventional clinical trial is a disposable asset A sponsor writes a protocol for a single compound activates a network of sites recruits a control group reads out and then dismantles everything it has built When the next candidate arrives often in the same disease often at the same hospitals

    Unveiling Hope: Progress and Challenges in Rare Disease Drug Development

    Rare diseases often referred to as orphan diseases affect a small percentage of the population Despite their rarity these diseases collectively impact millions of people worldwide The development of drugs

    How Digitalization Improves Pharma Manufacturing and Compliance

    The pharmaceutical industry has been at a crossroads where the digitalization process is transforming the way drugs are developed manufactured and monitored Pharmaceutical companies are capitalizing on the power of digitalization in pharmaceutical production to maximize production improve traceability and regulatory compliance due to the tough regulatory requirements and the demand for absolute pr...

TOP ARTICLES

press releases Read more...

Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat

Erasca Inc Nasdaq ERAS a clinicalstage precision oncology company singularly focused on discovering developing and commercializing therapies for patients with RASMAPK pathwaydriven cancers today announced a clinical

Verismo Therapeutics Licenses In Vivo CAR T Engineering Technology to Extend Its Novel Multi-Chain KIR-CAR Platform

Verismo Therapeutics a clinicalstage CAR T cell therapy company pioneering a novel multichain KIRCAR platform technology announced today that the company licensed the PACKIT technology enabling in vivo engineering of KIRCAR

22nd Edition Project Portfolio and Resource Management Excellence for Pharma and BioTech

Pharma organisations are still in a transition process from traditional model centered on blockbuster to more collaborative global ones In order to address the main challenge of RD productivity PPM professional serve as a link between operational teams

Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development

Cancer Research UK and Dewpoint Therapeutics today announced a collaboration and licence agreement to advance DPTX a potential firstinclass small molecule modulator of MYC condensates into clinical development

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

25 - 25

Nov 2026

What’s Next for Pharma Marketing in 2027

Landesmuseum Zürich, Zurich, S...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

LATEST NEWS Read more...

CAI Enters Agreement with PQE Group to Expand Global Life Sciences Services

CAI a professional services firm specialising in operational readiness and excellence for life sciences and other critical industries has entered into a definitive agreement with PQE Group a global consulting firm focused on quality compliance

Erasca Partners with Bristol Myers Squibb to Study ERAS-0015 Combination Therapy for Pancreatic Cancer

Erasca Inc a clinicalstage precision oncology company focused on developing treatments for cancers driven by the RASMAPK signalling pathway has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMS

Libtayo Receives EU Approval for Extended Dosing and Shorter Infusion Times Across Six Cancer Indications

Regeneron Pharmaceuticals has received European Commission EC approval for an alternative dosing schedule for Libtayo cemiplimab across all six of its approved indications for skin lung and cervical cancers in the European Union EU

FDA approves Roche’s Wilserdly for ER-positive, ESR1-mutated advanced breast cancer

Roche has received approval from the US Food and Drug Administration FDA for Wilserdly giredestrant in combination with everolimus to treat adults with oestrogen receptor ERpositive human epidermal growth factor receptor HERnegative ESRmutated locally advanced or metastatic breast cancer

European Commission approves Revolution Medicines’ RASONQUE for metastatic pancreatic cancer

Revolution Medicines has received European Commission EC approval for RASONQUE daraxonrasib to treat adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy The medicine is taken once daily as an oral tablet and is approved for patients with or witho...

Immuneering and Astellas to Evaluate Combination Treatments for CLDN18.2-Expressing Pancreatic Cancer

Immuneering Corporation Nasdaq IMRX has entered into a clinical trial collaboration and supply agreement with Astellas Pharma Global Development Inc a subsidiary of Astellas Pharma Inc TSE to evaluate combination treatments for patients with pancreatic cancer whose tumours express CLDN